SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000926617-23-000083
Filing Date
2023-10-13
Accepted
2023-10-13 17:21:52
Documents
12
Period of Report
2023-10-13
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 8-K awh-20231013x8k.htm   iXBRL 8-K 57160
  Complete submission text file 0000926617-23-000083.txt   181894

Data Files

Seq Description Document Type Size
2 EX-101.SCH awh-20231013.xsd EX-101.SCH 2552
3 EX-101.LAB awh-20231013_lab.xml EX-101.LAB 15614
4 EX-101.PRE awh-20231013_pre.xml EX-101.PRE 11196
6 EXTRACTED XBRL INSTANCE DOCUMENT awh-20231013x8k_htm.xml XML 5066
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 231325749
SIC: 2835 In Vitro & In Vivo Diagnostic Substances